(Reuters) - The regulatory green light represents a small piece of good
news for Europe's biggest drugmaker, whose shares have fallen
more than 7 percent this week due to safety fears over its
diabetes medicine Avandia.
The stock was 1.2 percent down on the day at 1100 GMT.
Read more at Reuters.com Government Filings News
news for Europe's biggest drugmaker, whose shares have fallen
more than 7 percent this week due to safety fears over its
diabetes medicine Avandia.
The stock was 1.2 percent down on the day at 1100 GMT.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment